BLAST-OFFNCT07181590
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
StatusActive, Not Recruiting
PhaseNot applicable
SponsorAbbott Medical Devices
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 45 words Show 4 more changesShow less
- Primary endpoints: details revised at 2 of 3 entries
- Enrollment closed, study ongoing
- Primary and study completion dates: Aug 2027 to Sep 2027
- Site details revised at 22 of 22 sites
- Minor Site details revised at 4 of 22 sitesv5
- Minor Site details revised at 2 of 22 sitesv4
- Minor Site details revised at 10 of 22 sitesv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 22
- Start date changed from estimate of Dec 2025 to Dec 11, 2025
- Interventions: Pulsed Field Ablation (Procedure) to Pulsed Field Ablation (Device)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Rate of subjects experiencing a device and/or procedure-related serious adverse event with onset within 7 days of any ablation procedure that uses Volt AF
Timeframe: 7 days
Long-term Effectiveness will be the proportion of subjects with freedom from documented AF/AFL/AT recurrence through 12-months.
Timeframe: During procedure
Acute procedural effectiveness is defined as confirmation of entrance block in all targeted pulmonary veins
Timeframe: During procedure
Arms and interventions
Volt PFA Catheter Sensor Enabled (SE)Other
Patients diagnosed with drug refractory, symptomatic, recurrent, paroxysmal and persistent atrial fibrillation that will undergo a de novo ablation procedure with the Volt PFA Catheter.
Devices: Pulsed Field Ablation
Sites
22 sites in 12 countries
Germany 4, France 3, Spain 3, Belgium 2, Italy 2, Netherlands 2, Austria 1, Denmark 1, Ireland 1, Poland 1, Portugal 1, Sweden 1